SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 04:35:01 2024-05-23 am EDT | ||
| 26.65 EUR | +1.60% |
|
| Current month | -5.48% | ||
| 1 month | -0.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 26.65 | +1.60% |
| 24-05-22 | 26.23 | -2.24% |
| 24-05-21 | 26.83 | +1.78% |
| 24-05-17 | 26.36 | -0.15% |
| 24-05-16 | 26.4 | +1.42% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 04:35 am EDT
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VX25JS |
| ISIN | DE000VX25JS3 |
| Date issued | 2021-11-05 |
| Strike | 4,022 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 16.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.46 € |
|---|---|
| Lowest since issue | 9.64 € |
| Spread | 0.02 € |
| Spread % | 0.07% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
2,055
DKK
Average target price
2,466
DKK
Spread / Average Target
+19.99%
- Stock Market
- Certificates
- Certificat
